1. Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis
- Author
-
Patrij, Katrin, Kowoll, Annika, Wätzel, Luise, Reiser, Marcel, Pels, Hendrik, Linnebank, Michael, Engert, Andreas, Herrlinger, Ulrich, Schackert, Gabriele, Vogt-Schaden, Marlies, Egerer, Gerlinde, Lamprecht, Monika, Batchelor, Tracy T., Schlegel, Uwe, Schmidt-Wolf, Ingo G. H., and International Primary CNS Lymphoma Collaborative Group (IPCG)
- Subjects
lymphoma ,neoplasia ,chemotherapy ,CNS ,relapse ,methotrexate ,Medicine - Abstract
We analyzed clinical outcome of patients with an isolated central nervous system lymphoma (CNSL) relapse after systemic non-Hodgkin’s lymphoma (NHL). All 23 patients with an isolated secondary CNSL (SCNSL) treated at two institutions from 04/2003–12/2007 were included into this analysis. At cerebral relapse, 15/23 patients were treated with a regimen consisting of high-dose methotrexate (Bonn protocol). After a median follow-up of 6.5 months (range 1–68), 15/23 (65%) patients with SCNSL had relapsed or progressed. HD (high-dose)- methotrexate (MTX) chemotherapy according to the Bonn protocol is effective concerning response rates; however, overall survival of patients with SCNSL seems to be impaired in comparison to relapses in primary CNSL (PCNSL).
- Published
- 2011